Compare SPOK & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | ALLO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.8M | 252.9M |
| IPO Year | 1992 | 2018 |
| Metric | SPOK | ALLO |
|---|---|---|
| Price | $13.09 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 164.4K | ★ 4.1M |
| Earning Date | 02-25-2026 | 11-06-2025 |
| Dividend Yield | ★ 9.45% | N/A |
| EPS Growth | ★ 12.68 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $139,739,000.00 | N/A |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $2.63 | $100.00 |
| P/E Ratio | $16.53 | ★ N/A |
| Revenue Growth | ★ 1.47 | N/A |
| 52 Week Low | $12.26 | $0.86 |
| 52 Week High | $19.31 | $3.78 |
| Indicator | SPOK | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 59.70 |
| Support Level | $12.86 | $1.62 |
| Resistance Level | $13.35 | $1.88 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 55.55 | 56.41 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.